Alnylam Pharmaceuticals Inc (ALNY) Insider Trading
- $71,277,732.32
- $466,199,393.74
- April 6, 2026
- Akshay Vaishnaw
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Nov. 18, 2019 | Director | 15,000 | $91.71 | Sell | $1,375,650.00 | |
| Oct. 22, 2019 | President | 58,913 | $89.99 | Sell | $5,301,580.87 | |
| Oct. 14, 2019 | CEO | 49,456 | $79.45 | Sell | $3,929,279.20 | |
| May 15, 2019 | CEO | 49,457 | $70.00 | Sell | $3,461,990.00 | |
| April 15, 2019 | Director | 15,000 | $88.23 | Sell | $1,323,450.00 | |
| Aug. 30, 2018 | COO | 2,500 | $120.00 | Sell | $300,000.00 | |
| July 25, 2018 | CEO | 50,000 | $105.39 | Sell | $5,269,500.00 | |
| June 20, 2018 | SVP | 1,563 | $105.04 | Sell | $164,177.52 | |
| March 26, 2018 | COO | 7,221 | $136.54 | Sell | $985,955.34 | |
| March 20, 2018 | SVP | 1,562 | $149.83 | Sell | $234,034.46 | |
| March 14, 2018 | Insider | 88,554 | $143.10 | Sell | $12,672,077.40 | |
| March 14, 2018 | President | 38,460 | $143.10 | Sell | $5,503,626.00 | |
| March 13, 2018 | SVP | 20,000 | $145.00 | Sell | $2,900,000.00 | |
| March 13, 2018 | Director | 27,823 | $150.00 | Sell | $4,173,450.00 | |
| March 9, 2018 | Director | 15,000 | $129.00 | Sell | $1,935,000.00 | |
| Jan. 4, 2018 | VP | 36,745 | $131.59 | Sell | $4,835,274.55 | |
| Dec. 20, 2017 | SVP | 6,249 | $121.20 | Sell | $757,378.80 | |
| Dec. 1, 2017 | SVP | 30,000 | $135.89 | Sell | $4,076,700.00 | |
| Nov. 22, 2017 | CEO | 73,415 | $130.90 | Sell | $9,610,023.50 | |
| Nov. 15, 2017 | CEO | 74,000 | $126.86 | Sell | $9,387,640.00 | |
| Nov. 2, 2017 | Director | 20,000 | $130.00 | Sell | $2,600,000.00 | |
| Oct. 30, 2017 | EVP | 33,666 | $121.46 | Sell | $4,089,072.36 | |
| Oct. 2, 2017 | President | 85,316 | $125.00 | Sell | $10,664,500.00 | |
| Sept. 20, 2017 | President | 76,815 | $100.00 | Sell | $7,681,500.00 | |
| May 31, 2017 | Major Shareholder | 297,501 | $71.87 | Buy | $21,381,396.87 | |
| May 30, 2017 | SVP | 11,500 | $65.35 | Buy | $751,525.00 | |
| May 23, 2017 | EVP | 11,000 | $75.00 | Sell | $825,000.00 | |
| May 16, 2017 | VP | 9,375 | $70.00 | Sell | $656,250.00 | |
| May 15, 2017 | SVP | 43,750 | $65.00 | Sell | $2,843,750.00 | |
| Jan. 25, 2017 | Director | 15,000 | $37.95 | Sell | $569,250.00 | |
| Jan. 18, 2017 | Director | 15,000 | $37.83 | Sell | $567,450.00 | |
| Nov. 30, 2016 | CMO | 29,165 | $44.99 | Sell | $1,312,133.35 | |
| Oct. 13, 2016 | Director | 27,900 | $37.00 | Buy | $1,032,300.00 | |
| July 20, 2016 | CEO | 30,151 | $64.69 | Sell | $1,950,468.19 | |
| April 20, 2016 | CEO | 30,151 | $67.46 | Sell | $2,033,986.46 | |
| March 9, 2016 | Director | 2,000 | $58.36 | Buy | $116,720.00 | |
| Feb. 22, 2016 | SVP | 1,000 | $62.75 | Buy | $62,750.00 | |
| Feb. 1, 2016 | Major Shareholder | 205,030 | $69.75 | Buy | $14,300,842.50 | |
| Jan. 20, 2016 | CEO | 30,152 | $71.78 | Sell | $2,164,310.56 | |
| Dec. 4, 2015 | Director | 30,000 | $109.00 | Sell | $3,270,000.00 | |
| Dec. 2, 2015 | CEO | 58,689 | $104.87 | Sell | $6,154,715.43 | |
| Nov. 20, 2015 | CEO | 58,690 | $102.88 | Sell | $6,038,027.20 | |
| Nov. 12, 2015 | Director | 75,000 | $103.89 | Sell | $7,791,750.00 | |
| June 16, 2015 | CMO | 8,750 | $128.83 | Sell | $1,127,262.50 | |
| May 12, 2015 | Director | 2,000 | $112.16 | Buy | $224,320.00 | |
| April 21, 2015 | Director | 10,000 | $130.02 | Sell | $1,300,200.00 | |
| March 19, 2015 | Director | 5,000 | $120.00 | Sell | $600,000.00 | |
| March 17, 2015 | CMO | 8,750 | $116.86 | Sell | $1,022,525.00 | |
| Jan. 29, 2015 | Major Shareholder | 97,118 | $95.00 | Buy | $9,226,210.00 | |
| Jan. 26, 2015 | Director | 1,000 | $95.00 | Buy | $95,000.00 |
Insiders are both buying and selling Alnylam Pharmaceuticals Inc stock.
The insider traders at Alnylam Pharmaceuticals Inc are: John Maraganore, Akshay Vaishnaw, Yvonne Greenstreet, Pushkal Garg, Laurie Keating, Barry E Greene, Tolga Tanguler, Kevin Joseph Fitzgerald, Jeffrey V Poulton, Philip A Sharp, Michael Mason, Paul Schimmel, Dennis A Ausiello, Laurence Reid, Michael W Bonney, Sanofi, Steven M Paul, Kevin P Starr, Phillip A Sharp, Melissa Mclaughlin, Indrani Lall Franchini, David E I Pyott, Amy W Schulman, David-Alexandre C Gros, John Clarke, Kevin P. Starr, Marsha Fanucci, Philip A. Sharp, Phillip A. Sharp, and Colleen F Reitan
The most active insider trader at Alnylam Pharmaceuticals Inc is John Maraganore with 23 trades.
John Maraganore has sold the most Alnylam Pharmaceuticals Inc stock with a total value of $118,340,674.92.
Sanofi has bought the most Alnylam Pharmaceuticals Inc stock with a total value of $89,326,528.48.
The most recent insider trade for Alnylam Pharmaceuticals Inc was on April 6, 2026.
The single biggest insider buy for Alnylam Pharmaceuticals Inc was from Sanofi with a total value of $23,036,682.24 on March 25, 2014.
The single biggest insider sell for Alnylam Pharmaceuticals Inc was from Pushkal Garg with a total value of $14,988,720.00 on Jan. 27, 2025.